岩手医科大学医学部内科学講座リウマチ・膠原病・アレルギー内科|医歯薬総合研究所分子病態解析部門
講座紹介

研究・業績

01.サイトカインシグナル阻害分子SOCSの発見と癌治療への応用
サイトカインシグナル阻害分子SOCSの発見と癌治療への応用

 我々は1997年に、サイトカインシグナル伝達の主要な経路であるJAK-STATシグナル伝達経路を抑制する分子としてSOCS-1(Suppressor Of Cytokine Signaling)をクローニングした(Naka et al., Nature 1997)。その後、SOCS-1 KOマウスの作製により、SOCS-1がin vivoにおいてもJAK-STATシグナル伝達経路を抑制する分子であり、SOCS-1の欠損によりJAK-STATシグナル伝達が恒常的に活性化されて、多臓器にわたり炎症が惹起され、3週間以内にマウスが死亡することを明らかにした(Naka et al., immunity 2001)。また、ヒトのがんにおけるSOCS-1の発現異常(Komazaki et al. Jpn J Clin Oncol 2004)や遺伝子異常、さらにSOCS-1 HE KOマウスは自己免疫疾患を発症することなども明らかにし(Fujimoto et al. Int Immunol 2004) 、SOCS-1と炎症・がんとの関連を明らかにした。
 JAK-STATシグナル伝達経路(主にSTAT3)の恒常的活性化が癌細胞の生存や増殖に深く関わることから、STAT3の活性化を制御するSOCS-1/SOCS-3に注目し、アデノウイルスベクターを用いたSOCS遺伝子治療法の開発に着手している。これまでに、非増殖型アデノウィルスベクターにSOCS-3遺伝子を組み込み、悪性胸膜中皮腫の担癌モデルマウスに投与し、高い抗腫瘍活性を持つことを確認している(Iwahori et al., Int J Cancer 2011)。今後、難治性癌の1つである胸膜胸膜中皮腫を対象に医師主導型治験をがんセンター東病院で行うべく研究を進めている。将来的には、頭頚部腫瘍、肺癌(Shimada et al., Cancer Sci 2013)、胃癌(Souma et al., Int J Cancer 2012, Natatsuka et al., Br J Cancer 2015)、食道癌(Sugase et al., Int J Cancer 2017, Sugase et al., Cancer Res 2017)、肝臓癌、皮膚癌(Tagami-Nagata et al., Exp Dermatol 2015) などの難治性癌も視野に入れた開発を行う予定である。

02.Glypican-1を標的とした難治性固形癌に対する革新的抗体医薬品開発
Glypican-1を標的とした難治性固形癌に対する革新的抗体医薬品開発2 Glypican-1を標的とした難治性固形癌に対する革新的抗体医薬品開発2-2

 我々は難治性癌に対する創薬標的分子の探索を目的として、定量的プロテオミクス手法を用いて、食道癌に高発現する細胞膜タンパク質の発現解析を行った。その結果、食道癌に有意に高く発現している細胞膜蛋白質としてGlypican-1(GPC1)を同定した(Hara et al., Br J Cancer, 2016)。食道癌手術組織を用いた詳細な解析の結果、GPC1は食道癌組織にて高発現していることやリンパ節など転移先の臓器にも発現が保持されること、GPC1の発現が高い程、予後が悪いことを明らかにした。さらに、難治性癌である膵臓癌においてもGPC1が原発のみならずリンパ節や肝臓など遠隔転移部位にも高発現を示すことと、GPC1の高発現は膵臓癌においても予後不良となることを明らかにした(Nishigaki et al., Br J Cancer, 2020)。興味深いことにGPC1は膵臓癌組織において癌細胞だけでなく、癌関連線維芽細胞(cancer associated fibroblast:CAF)にも高発現を示すが、非癌部位の線維芽細胞では発現しない(論文投稿中)。GPC1は、heparan sulphate proteoglycans (HSPGs)ファミリーの分子の1つであり、FGF-2、HGF、HB-EGFなどのheparin-binding growth factors(HBGFs) の共役受容体として機能することが知られており、癌の増殖や転移を促進することも報告されている。そこで、我々はGPC1が難治性癌に対する治療標的になり得るのではないかと抗体医薬の開発を着手した。
 近年、モノクローナル抗体を利用して抗癌剤を癌細胞に特異的に送達する技術として抗体薬物複合体(Antibody-drug conjugate: ADC)が注目されている。ADCはモノクローナル抗体にリンカーを介して抗癌剤を結合させたものである。正常組織に発現しておらず癌組織に発現を示す抗原に対するモノクローナル抗体をADC化し、癌患者に投与すると癌抗原を発現する癌組織特異的に抗癌剤を輸送することが出来るため、癌細胞への薬効を保持しつつ、正常組織への毒性を軽減させることが可能となる。我々はGPC1がADCの標的として有用であるのではないかと考え、抗GPC1モノクローナル抗体を作成したところ、複数クローン樹立することに成功した。これらのクローンの内、細胞内侵入活性の高い抗GPC1モノクローナル抗体を数種類のクローンを取得することに成功した。そして、細胞内侵入活性を有する抗GPC1抗体に強力な微小管重合阻害剤であるMonomethyl auristatin F (MMAF)をコンジュゲートすることでADC化したGPC1-ADC(MMAF)を独自に開発することに成功した。GPC1-ADC(MMAF)はin vitroでGPC1陰性細胞には細胞増殖阻害を示さず、GPC1陽性細胞に対しては強力な細胞増殖阻害活性を示した(Matsuzaki et al., Int J Cancer, 2017, Nishigaki et al., Br J Cancer, 2020, Yokota et al., MCT, 2021) 。さらに、担癌マウスを用いた薬効解析の結果、GPC1-ADC(MMAF)はGPC1を発現する腫瘍に対して抗癌剤を特異的に輸送し、高い抗腫瘍効果と安全性を発揮すること明らかにした(Matsuzaki et al., Int J Cancer, 2017, Nishigaki et al., Br J Cancer, 2020, Yokota et al., MCT, 2021)。
 膵臓癌は間質が多く、間質のバリアによって癌細胞への抗癌剤の送達が妨害されることが膵臓癌における化学療法に抵抗性を示す原因の1つとして考えられている。そのため、膵臓癌のように間質が豊富な難治性癌においては、間質のバリアを克服するような治療戦略が必要である。そこで、我々は細胞膜透過性を有し、バイスタンダー効果を有するペイロードであるMonomethyl auristatin E (MMAE)をコンジュゲートしたGPC1-ADC(MMAE)を作成した。膵臓癌PDXを用いた解析の結果、GPC1-ADC(MMAE)はGPC1陽性のCAFに取り込まれ、CAF内部でリンカーが切断されて生じたMMAEがCAFから細胞外にMDR1を介して排出され、CAF周囲の膵臓癌細胞に対して抗腫瘍効果を発揮することを確認した(論文投稿中)。これらの結果、GPC1を標的としたADCは間質が豊富な難治性癌である膵臓癌などに対しても画期的な治療薬になり得る可能性が示唆された。これまでに抗GPC1モノクローナル抗体のヒト化、ADC化も完了しており(Munekage et al., Neoplasia, 2021)。現在、GPC1を標的とした難治性癌に対する新たな抗癌抗体医薬品の開発を進行中である。

03.LSRを標的とした難治性固形癌に対する革新的抗体医薬品開発
LSRを標的とした難治性固形癌に対する革新的抗体医薬品開発

 卵巣癌は予後不良な悪性疾患であり、臨床・基礎研究の重要度が高い腫瘍である。卵巣癌は無症状で経過することが多く、症状を呈する時点では進行癌となっていることが多い。そのため診断時には70%以上がIII期以上の進行癌であり、進行癌の5年生存率は40%と低い。治療は、手術・化学療法が中心であるが、完全切除が不可能な症例も多い。
 当研究室では卵巣癌細胞における細胞膜タンパク質の網羅的発現解析を行い、高発現を示す分子としてlipolysis-stimulated lipoprotein receptor (LSR) を同定し、この高発現が卵巣癌の予後不良因子であることを発見した(Hiramatsu, et al., Cancer Res, 2018)。LSRは正常卵巣組織と比較して卵巣癌組織において高く発現し、LSR高発現患者群は低発現患者群と比較して有意に予後不良であった。LSRは卵巣癌のリンパ節転移や大網転移先の癌細胞にも発現しており、癌の転移や腹膜播種などにも関与している可能性がある。
 LSRは正常細胞においては脂質の細胞内取り込みや細胞接着分子として機能する分子として報告されている。しかしながら癌細胞におけるLSRの機能はまだ完全には明らかにされていない。我々は独自に開発した抗LSRモノクローナル抗体を用いてヒト卵巣癌細胞株移植マウスおよび卵巣癌組織を移植したPDXマウスに対して抗腫瘍効果の検討を行ったところ、抗LSR抗体はADCC活性非依存的な強い抗腫瘍活性を有することをin vivoで明らかにした。この際、抗LSR抗体投与により、癌細胞内の脂肪滴が減少したことから、抗LSR抗体が腫瘍組織内への脂質取り込みを抑制することも確認した。LSR陽性癌細胞はグルコース、FBS欠損培地でVLDLを細胞内に取り込み、細胞の増殖・生存作用を発揮する。そして、抗LSR抗体はLSRによるVLDLの細胞内への取り込みを阻害することで、VLDLを介した癌細胞の増殖・生存作用を阻害することから、LSRを標的とする抗癌剤は脂質代謝を標的とする新たな抗癌剤としての実用化が期待される。当部門では卵巣癌の増殖・生存・腹膜播種におけるLSRの機能解析と並行し、抗LSR抗体による抗腫瘍効果の詳細な作用機序を明らかにし、LSR陽性卵巣癌など難治性癌に対する新規抗体医薬の実用化を目指した研究を行っている。

04.リウマチ・膠原病疾患の多施設産学連携オミクス研究
―免疫炎症性難病創薬コンソーシアム―

 我々のグループでは、複数アカデミア(慶應義塾大学、高知大学、医薬基盤・健康・栄養研究所)と複数企業(田辺三菱製薬、小野薬品工業、第一三共製薬)と協力して連携体制を組み、免疫炎症性難病を対象に創薬を目標とするマルチオミクス研究を実施している。各大学の附属病院において、正確な診断と適切な治療を受けている免疫炎症性難病患者さんの貴重な検体を治療前後で収集し、フローサイトメトリーによる免疫細胞のフェノタイピング、免疫細胞のトランスクリプトーム解析、血清のプロテオミクス解析によって詳細かつ網羅的なデータ取得を行い、医薬基盤・健康・栄養研究所において臨床情報とともにデータベースへと順次集積していく。製薬各社およびアカデミアはこのデータベースを活用してシーズ探索を行い、独自の基礎・応用研究に取り組みながら免疫炎症性難病の病態解明や創薬を目指す。このような多施設共同の枠組みは、従来型のアカデミアと企業との一対一の共同研究の弱点克服を目指して、難病患者さんの貴重な検体とそのオミクスデータを参加施設内の共有財産とするものであり、希少難病研究の効率化と活性化をはかるユニークな試みである。

05.難治性疾患における疾患関連蛋白の探索的研究
―新たな炎症マーカーLRGの開発と適応拡大への試み―

 我々はプロテオミクス解析の手法を応用して、治療前・後の関節リウマチ患者血清に含まれる蛋白質を網羅的に分析し、治療前(活動期)で有意に上昇して治療後に速やかに低下する蛋白質Leucine-rich alpha-2-glycoprotein (LRG)を同定した(Serada et al., Ann Rheum Dis. 2010)。LRGは肝細胞で産生される血清蛋白として知られていたが、我々の一連の解析から、IL-6、TNF-α、IL-22といった炎症性サイトカインによってLRGの発現が誘導され (Serada et al., Inflamm Bowel Dis. 2012)、しかも炎症部位では様々な細胞(上皮細胞やマクロファージ、好中球など)からLRGが産生されていることが明らかになった。現在、炎症マーカーとして使われているC反応性蛋白質(CRP)は、IL-6依存的に肝細胞で産生され、その他の炎症性サイトカインの刺激や他の細胞ではほぼ発現が誘導されない。したがって、LRGはより広範な疾患病態で炎症マーカーとして利用できる可能性がある。事実、IL-6阻害治療中の関節リウマチ患者においては、CRP発現自体が抑制されるためCRPを疾患活動性マーカーとして使うことが出来ないが、LRGは様々な炎症性サイトカインにより炎症局所で産生されるために、IL-6阻害中でも疾患活動性に応じた上昇が認められる (Fujimoto et al., Arthritis Rheumatol. 2015)。また、病勢がCRPに反映されないことがある潰瘍性大腸炎では、血清LRGがCRPよりも疾患活動性と良く相関することが明らかになった(Shinzaki et al., J Crohns Colitis. 2017)。この成果を契機に臨床検査用のLRG測定系開発が着々と進められ、LRGは2020年に潰瘍性大腸炎やクローン病に対する疾患活動性評価マーカーとして保険収載されることになった。これまで、我々のグループでは、乾癬、皮膚筋炎の肺病変、新生児感染症などにおいて、血清LRGが疾患活動性マーカーとして有用性を発揮する事を明らかにしており(Nakajima et al., J Dermatol Sci. 2017, Fujimoto et al., Sci Rep. 2020, Ishida et al., PLoS One. 2020, Kajimoto et al., PLoS One. 2020)、より多くの疾患の診療にLRGを応用することを目指している。
 我々はまた、LRGの機能面についても検討も行なっている。LRGノックアウトマウスを独自に作製して、マウスにさまざまな疾患を誘発させたところ、関節炎が軽減されたり (Urushima et al., Arthritis Res Ther. 2017)、肺線維症が軽減されたり(Honda et al., Physiol Rep. 2017)、乾癬様皮膚炎が軽減されたり(Nakajima et al. J Immunol, 2021)することが明らかになった。このことはLRGが炎症の増悪に何らかの形で関わっていることを示唆している。現在、様々な疾患マウスモデルを用いてLRGの機能面での解析を行い、創薬標的としてのLRGの評価を行っている。

難治性疾患における疾患関連蛋白の探索的研究
06.中枢神経症状を呈する自己免疫疾患の微小脳血管における血管炎の検出

 中枢神経系の症状を呈する自己免疫疾患の診断において、画像、特にMRI画像は血清、髄液とともに病態の総合的判断材料として広く用いられている。しかし、臨床的に中枢神経症状が明らかであっても、通常診療で使われるMRI(1.5テスラ(T), 3T)では異常が検出されないケースがあり、これは小型血管よりもさらに細い血管(微小脳血管)に炎症の主座が存在する可能性がある(Murata et al. Neuroreport, 2015)。本研究では、髄液、血清のサイトカインプロファイルおよび急性期タンパクなどの炎症マーカーを新たに評価するとともに、高磁場MRI(7T)を用いて従来のMRIでは検出できない微小脳血管炎を描出し、炎症マーカーの動きと得られた画像所見との関連を調べる。現状では診断が困難な自己免疫疾患の中枢神経病変について、新たなマーカーや評価指標を開発することを目指す。

2022

1) Nakatani K, Serada S, Fujimoto M, Obata K, Ohkawara T, Sasabe E, Yamamoto T, Naka T.
Gene therapy with SOCS1 induces potent preclinical antitumor activities in oral squamous cell carcinoma.
Journal of Oral Pathology and Medicine. 2022 Feb;51(2):126-133. [PubMed]
2) Kajiyama T, Serada S, Fujimoto M, Ohkawara T, Komori M, Hyodo M, Naka T.
SOCS1 gene therapy for head and neck cancers: an experimental study.
Anticancer Res. 2022 In Press Corresponding author

2021

1) Takahashi Y, Serada S, Ohkawara T, Fujimoto M, Hiramatsu K, Ueda Y, Kimura T, Takemori H, Naka T.
LSR promotes epithelial ovarian cancer cell survival under energy stress through the LKB1-AMPK pathway.
Biochem Biophys Res Commun. 2021 Jan 22;537:93-99. [PubMed]
2) Nakae R, Matsuzaki S, Serada S, Matsuo K, Shiomi M, Sato K, Nagase Y, Matsuzaki S, Nakagawa S, Hiramatsu K, Okazawa A, Kimura T, Egawa-Takata T, Kobayashi E, Ueda Y, Yoshino K, Naka T, Kimura T.
CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma
Am J Obstet Gynecol . 2021 Feb;224(2):197.e1-197.e23. [PubMed]
3) Nakajima H, Nakajima K, Serada S, Fujimoto M, Naka T, Sano S.
The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model.
Mod Rheumatol . 2021 Feb 17:1-10. [PubMed]
4) Nakajima H, Nakajima K, Takaishi M, Ohko K, Serada S, Fujimoto M, Naka T, Sano S.
The skin-liver axis modulates the psoriasiform phenotype and involves leucine-rich α-2 glycoprotein
J Immunol . 2021 Apr 1;206(7):1469-1477. [PubMed]
5) Koh M, Kurokawa Y, Kobayashi T, Saito T, Ishida T, Serada S, Fujimoto M, Naka T, Wada N, Yamashita K, Tanaka K, Miyazaki Y, Makino T, Nakajima K, Yamasaki M, Eguchi H, Doki Y.
Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis.
Gastric Cancer . 2021 In Press [PubMed]
6) Yokota K, Serada S, Tsujii S, Toya K, Takahashi T, Matsunaga T, Fujimoto M, Uemura S, Namikawa T, Murakami I, Kobayashi S, Eguchi H, Doki Y, Hanazaki K, Naka T.
Anti-glypican-1 antibody–drug conjugate as potential therapy against tumor cells and tumor vasculature for glypican-1 positive cholangiocarcinoma.
Mol Cancer Ther . 2021 In Press [PubMed]
7) Shibata Y, Nakajima H, Nakajima K, Serada S, Fujimoto M, Naka T, Sano S.
Leucine-rich α-2 glycoprotein is a predictive marker of therapeutic efficacy of the biologics in psoriatic arthritis.
Journal of Cutaneous Immunology and Allergy . 2021 In Press
8) Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T, Shiotani A, Hirai F, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T.
Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
J Gastroenterol . 2021 Jun;56(6):560-569. [PubMed]
9) Shiomi M, Matsuzaki S, Serada S, Matsuo K, Mizuta-Odani C, Jitsumori M, Nakae R, Matsuzaki S, Nakagawa S, Hiramatsu K, Miyoshi A, Kobayashi E, Kimura T, Ueda Y, Yoshino K, Naka T, Kimura T.
CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer.
Cancer Sci . 2021 In Press [PubMed]
10) Munekage E, Serada S, Tsujii S, Yokota K, Kiuchi K, Tominaga K, Fujimoto M, Kanda M, Uemura S, Namikawa T, Nomura T,Murakami T, Hanazaki K, Naka T.
A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Neoplasia . 2021 In Press [PubMed]
11) Yanai S, Shinzaki S, Matsuoka K, Mizuno S, Iijima H, Naka T, Kanai T, Matsumoto T.
Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study.
Digestion . 2021 Jul 16:1-9. [PubMed]
12) Tsujii S, Serada S, Fujimoto M, Uemura S, Namikawa T, Nomura T,Murakami I, Hanazaki K, Naka T.
Glypican-1 is a novel target for stroma and tumor cell dual-targeting antibody-drug conjugates in pancreatic cancer.
Mol Cancer Ther. 2021 Dec;20(12):2495-2505. [PubMed]
13) Ishida T, Takahashi T, Kurokawa Y, Nishida T, Hirota S, Serada S, Fujimoto M, Naka T, Teranishi R, Saito T, Yamashita K, Tanaka K, Yamamoto K, Makino T, Yamasaki M, Nakajima K, Eguchi H, Doki Y.
Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours.
Br J Cancer. 2021 Nov;125(11):1511-1522. [PubMed]

2020

1) Kakuda M, Matsuzaki S, Ueda Y, Shiomi M, Matsuzaki s, Kimura T, Fujita M, Egawa-Takata T, Kobayashi E, Serada S, Yoshino K, Naka T, KimuraT.
Copper ions are novel therapeutic agents for uterine leiomyosarcoma
Am J Obstet Gynecol . 2020 Jan;222(1):64.e1-64.e16. [PubMed]
2) Saito Y, Takahashi T, Obata Y, Nishida T, Ohkubo S, Nakagawa F, Serada S, Fujimoto M, Ohkawara T, Nishigaki T, Sugase T, Koh M, Ishida T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Nakajima K, Yamasaki M, Hirota S, Naka T, Mori M, Doki Y.
TAS-116 inhibits oncogenic KIT signaling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumors
Br J Cancer . 2020 Mar;122(5):658-667. [PubMed]
3) Nishigaki T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hara H, Sugase T, Otsuru T, Saito Y, Tsujii S, Nomura T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Nakajima K, Eguchi H, Yasamaki M, Mori M, Doki Y, Naka T.
Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.
Br J Cancer . 2020 Apr;122(9):1333-1341. [PubMed]
4) Fujimoto M, Matsumoto T, Serada S, Tsujimura Y, Hashimoto S, Yasutomi Y, Naka T.
Leucine-rich alpha 2 glycoprotein is a new marker for active disease of tuberculosis.
Scientific Reports . 2020 Feb 25;10(1):3384. [PubMed]
5) Kato D, Yaguchi T, Iwata T, Katoh Y, Morii K, Tsubota K, Takise Y, Tamiya M, Kamada H, Akiba H, Tsumoto K, Serada S, Naka T, Nishimura R, Nakagawa T, Kawakami Y.
GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab.
eLife . 2020 Mar 31;9:e49392. [PubMed]
6) Jin Z, Kobayashi S, Gotoh K, Takahashi T, Eguchi H, Naka T, Mori M, Doki Y.
The Prognostic Impact of Leucine-Rich α-2-Glycoprotein-1 in Cholangiocarcinoma and Its Association With the IL-6/TGF-β1 Axis.
J Surg Res . 2020 Apr 9;252:147-155. [PubMed]
7) Adachi T, Yasuda K, Muto T, Serada S, Yoshimoto T, Ishii KJ, Kuroda E, Araki K, Ohmuraya M, Naka T, Nakanishi K.
Lung fibroblasts produce interleukin-33 in response to stimulation by retinoblastoma-binding protein 9 via production of prostaglandin E2.
International Immunology . 2020 Sep 30;32(10):637-652. [PubMed]
8) Ishida T, Kotani T, Serada S, Fujimoto M, Takeuchi T, Makino M, Naka T.
Correlation of increased serum leucine-rich α2-glycoprotein levels with disease prognosis, progression, and activity of interstitial pneumonia in patients with dermatomyositis: A retrospective study
PLoS One . 2020 Jun 1;15(6):e0234090. [PubMed]
9) Kajimoto E, Endo M, Fujimoto M, Matsuzaki S, Fujii M, Yagi K, Kakigano A, Mimura K, Tomimatsu T, Serada S, Takeuchi M, Yoshino K, Ueda Y, Kimura T, Naka T.
Evaluation of leucine-rich alpha-2-glycoprotein as a biomarker of fetal infection.
PLoS One . 2020 Nov 19;15(11):e0242076. [PubMed]

2019

1) Yoneda T, Kunimura N, Kitagawa K, Fukui Y, Saito H, Narikiyo K, Ishiko M, Otsuki N, Nibu KI, Fujisawa M, Serada S, Naka T, Shirakawa T.
Overexpression of SOCS3 mediated by adenovirus vector in mouse and human castration resistant prostate cancer cells increases the sensitivity to NK cells in vitro and in vivo
Cancer Gene Therapy . 2019 Nov;26(11-12):388-399. [PubMed]
2) Otsuru T, Kobayashi S, Wada H, Takahashi T, Gotoh K, Iwagami Y, Yamada D, Noda T, Asaoka T, Serada S, Fujimoto M, Eguchi H, Mori M, Doki Y, Naka T.
Epithelial-mesenchymal transition via TGF-β in pancreatic cancer is potentiated by the inflammatory glycoprotein LRG.
Cancer Sci . 2019 Mar;110(3):985-996. [PubMed]
3) Shibata Y, Serada S, Fujimoto M, Ohko K, Oishi T, Fujieda M, Naka T, Sano S.
Myosin heavy chain, a novel allergen for fish allergy in patients with atopic dermatitis.
British Journal of Dermatology . 2019 Dec;181(6):1322-1324. [PubMed]

2018

1) Hiramatsu K, Serada S, Enomoto T, Takahashi Y, Nakagawa S, Nojima S, Morimoto A, Matsuzaki S, Yokoyama T, Takahashi T, Fujimoto M, Takemori H, Ueda Y, Yoshino K, Morii E, Kimura T, Naka T.
LSR antibody therapy inhibits ovarian epithelial tumor growth by inhibiting lipid uptake.
Cancer Res . 2018 Jan 15;78(2):516-527. [PubMed]
2) Matsuzaki S, Serada S, Hiramatsu K, Nojima S, Matsuzaki S, Ueda Y, Ohkawara T, Mabuchi S, Fujimoto M, Morii E, Yoshino K, Kimura T, Naka T.
Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
Int J Cancer . 2018 Mar 1;142(5):1056-1066. [PubMed]
3) Lee H, Ohkawara T, Honda H, Serada S, Terada Y, Naka T.
Leucine rich α-2 glycoprotein is a potential urinary biomarker for renal tubular injury.
Biochem Biophys Res Commun . 2018 Apr 15;498(4):1045-1051. [PubMed]
4) Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Nishida T, Hirota S, Saito Y, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanasaki K, Kishimoto T, Mori M, Doki Y, Naka T.
SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3K signaling.
Gastric Cancer . 2018 In Press [PubMed]
5) Kimura A, Kitajima M, Nishida K, Serada S, Fujimoto M, Naka T, Fujii-Kuriyama Y, Sakamato S, Ito T, Handa H, Tanaka T, Yoshimura A, Suzuki H.
NQO1 inhibits the TLR-dependent production of selective cytokines by promoting IκB-ζ degradation.
J Exp Med . 2018 Aug 6;215(8):2197-2209. [PubMed]
6) Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S, Matsuzaki S, Ueda Y, Yoshino K, Ohkawara T, Fujimoto M, Kishimoto K, Kimura T, Naka T.
Intratumoral delivery of an adenoviral vector carrying the SOCS-1 gene enhances T cell-mediated anti-tumor immunity by suppressing PD-L1.
Mol Cancer Ther . 2018 Sep;17(9):1941-1950. [PubMed]
7) Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Koh M, Saito Y, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanazaki K, Mori M, Doki Y, Naka T.
Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer.
Oncotarget . 2018 Aug 31;9(68):32917-32928. [PubMed]
8) Egawa-Takata T, Yoshino K, Hiramatsu K, Nakagawa S, Serada S, Nakajima A, Endo H, Kubota S, Matsuzaki S, Kobayashi E, Ueda Y, Morii E, Inoue M, Naka T, Kimura T.
Small Cell Carcinomas of the Uterine Cervix and Lung: Proteomics Reveals Similar Protein Expression Profiles.
Int J Gynecol Cancer . 2018 Nov;28(9):1751-1757. [PubMed]
9) Naka T, Fujimoto M.
LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease.
Immunol Med . 2018 Jun;41(2):62-67. [PubMed]

2017

1) Shinzaki S, Matsuoka K, Iijima H, Mizuno S, Serada S, Fujimoto M, Arai N, Koyama N, Morii E, Watanabe M, Hibi T, Kanai T, Takehara T, Naka T.
Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
J Crohns Colitis . J Crohns Colitis. 2017 Jan;11(1):84-91.  [PubMed]
2) Hosono Y, Nakashima R, Serada S, Murakami K, Imura Y, Yoshifuji H, Ohmura K, Naka T, Mimori T.
Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody.
J Autoimmun . 2017 Feb;77:116-122.  [PubMed]
3) Harada E, Serada S, Fujimoto M, Takahashi Y, Takahashi T, Hara H, Nakatsuka R, Sugase T, Nishigaki T, Saito Y, Hiramatsu K, Nojima S, Mitsuo R, Ohkawara T, Morii E, Mori M, Doki Y, Kaneda Y, Naka T.
Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma.
Oncotarget . 2017 Apr 11;8(15):24741-24752. [PubMed]
4) Takahashi T, Elzawahry A, Mimaki S, Furukawa E, Nakatsuka R, Nakamura H, Nishigaki T, Serada S, Naka T, Hirota S, Shibata T, Tsuchihara K, Nishida T, Kato M.
Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.
Genes Chromosomes Cancer . 2017 Apr;56(4):303-313.  [PubMed]
5) Shinzaki S, Iijima H, Fujii H, Kamada Y, Naka T, Takehara T, Miyoshi E.
A novel pathogenesis of inflammatory bowel disease from the perspective of glyco-immunology.
J Biochem . 2017 May 1;161(5):409-415. [PubMed]
6) Nakajima H, Serada S, Fujimoto M, Naka T, Sano S.
Leucine-rich α-2 glycoprotein is an innovative biomarker for psoriasis. J Dermatol Sci. 2017 May;86(2):170-174.  [PubMed]
7) Sugase T, Takahashi T, Serada S, Nakatsuka R, Fujimoto M, Ohkawara T, Hara H, Nishigaki T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Kishimoto T, Mori M, Doki Y, Naka T.
Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice.
Int J Cancer . 2017 Jun 1;140(11):2608-2621.  [PubMed]
8) Urushima H, Fujimoto M, Mishima T, Ohkawara T, Honda H, Lee H, Kawahata H, Serada S, Naka T.
Leucine-rich alpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement of TGF-β-Smad2 signaling in naïve helper T cells.
Arthritis Res Ther . 2017 Jun 14;19(1):137.  [PubMed]
9) Yamamoto M, Takahashi T, Serada S, Sugase T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Naka T, Mori M, Doki Y.
Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer.
Cancer Sci . 2017 Oct;108(10):2052-2060. [PubMed]
10) Sugase T, Takahashi T, Serada S, Fujimoto M, Hiramatsu K, Ohkawara T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Kishimoto T, Mori M, Doki Y, Naka T.
SOCS1 gene therapy improves radiosensitivity and enhances irradiation-induced DNA damage in esophageal squamous cell carcinoma.
Cancer Res . 2017 Dec 15;77(24):6975-6986. [PubMed]
11) Honda H, Fujimoto M, Serada S, Urushima H, Mishima T, Lee H, Ohkawara T, Kohno N, Hattori N, Yokoyama A, Naka T.
Leucine-rich α-2 glycoprotein promotes lung fibrosis by modulating TGF-β signaling in fibroblasts.
Physiological Reports . 2017 Dec;5(24). pii: e13556. [PubMed]

2016

1) Yang L, Murota H, Shindo S, Yang F, Serada S, Fujimoto M, Naka T, Katayama I.
Increased serum CXCR2 ligand levels in livedo vasculopathy with winter ulcerations: Possible contribution of neutrophil recruitment to lesional skin.
J Dermatol Sci . 82(1):57-9. 2016. [PubMed]
2) Mahmoud NF, Kawabata A, Tang H, Wakata A, Wang B, Serada S, Naka T, Mori Y.
Human herpesvirus 6 U11 protein is critical for virus infection.
Virology . 2016 Feb;489:151-7.  [PubMed]
3) Kumagai S, Nakayama H, Fujimoto M, Honda H, Serada S, Ishibashi-Ueda H, Kasai A, Obana M, Sakata Y, Sawa Y, Fujio Y, Naka T.
Myeloid cell-derived LRG attenuates adverse cardiac remodelling after myocardial infarction.
Cardiovasc Res . 2016 Feb 1;109(2):272-82.  [PubMed]
4) Yamada K, Miyamoto Y, Tsujii A, Moriyama T, Ikuno Y, Shiromizu T, Serada S, Fujimoto M, Tomonaga T, Naka T, Yoneda Y, Oka M.
Cell surface localization of importin α1/KPNA2 affects cancer cell proliferation by regulating FGF1 signalling.
Sci Rep . 2016 Feb 18;6:21410. [PubMed]
5) Hiramatsu K, Yoshino K, Serada S, Yoshihara K, Hori Y, Fujimoto M, Matsuzaki S, Egawa-Takata T, Kobayashi E, Ueda Y, Morii E, Enomoto T, Naka T, Kimura T.
Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas.
Br J Cancer. 2016 Mar 1;114(5):554-61.  [PubMed]
6) Yotsui I, Serada S, Naka T, Saruhashi M, Taji T, Hayashi T, Quatrano RS, Sakata Y.
Large-scale proteome analysis of abscisic acid and ABSCISIC ACID INSENSITIVE3-dependent proteins related to desiccation tolerance in Physcomitrella patens.
Biochem Biophys Res Commun . 2016 Mar 18;471(4):589-95. [PubMed]
7) Han Y, Ripley B, Serada S, Naka T, Fujimoto M.
Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation.
PLoS One . 2016 Apr 12;11(4):e0153399.  [PubMed]
8) Hara H, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Nakatsuka R, Harada E, Nishigaki T, Takahashi Y, Nojima S, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Morii E, Mori M, Doki Y, Naka T.
Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma.
Br J Cancer . 2016 Jun 28;115(1):66-75.   [PubMed]
9) Wada N, Kurokawa Y, Takahashi T, Hamakawa T, Hirota S, Naka T, Miyazaki Y, Makino T, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y.
Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor.
Oncology . 2016;90(2):112-7.  [PubMed]
10) Honda H, Fujimoto M, Miyamoto S, Ishikawa N, Serada S, Hattori N, Nomura S, Kohno N, Yokoyama A, Naka T.
Sputum Leucine-Rich Alpha-2 Glycoprotein as a Marker of Airway Inflammation in Asthma.
PLoS One . 2016 Sep 9;11(9):e0162672.  [PubMed]

2015

1) Furukawa K, Kawamoto K, Eguchi H, Tanemura M, Tanida T, Tomimaru Y, Akita H, Hama N, Wada H, Kobayashi S, Nonaka Y, Takamatsu S, Shinzaki S, Kumada T, Satomura S, Ito T, Serada S, Naka T, Mori M, Doki Y, Miyoshi E, Nagano H.
Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer.
Pancreas . 2015 Jan;44(1):93-8.  [PubMed]
2) Yang L, Fujimoto M, Murota H, Serada S, Fujimoto M, Honda H, Yamada K, Suzuki K, Nishikawa A, Hosono Y, Yoneda Y, Takehara K, Imura Y, Mimori T, Takeuchi T, Katayama I, Naka T.
Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud's phenomenon.
Rheumatology (Oxford) . 2015 Feb;54(2):349-58. [PubMed]
3) Takemoto N, Serada S, Fujimoto M, Honda H, Ohkawara T, Takahashi T, Nomura S, Inohara H, Naka T.
Leucine-rich α-2-glycoprotein promotes TGFβ1-mediated growth suppression in the Lewis lung carcinoma cell lines.
Oncotarget . 2015 May 10;6(13):11009-22.  [PubMed]
4) Sanosaka M, Fujimoto M, Ohkawara T, Nagatake T, Itoh Y, Kagawa M, Kumagai A, Fuchino H, Kunisawa J, Naka T, Takemori H.
Salt-inducible kinase 3 deficiency exacerbates lipopolysaccharide-induced endotoxin shock accompanied by increased levels of pro-inflammatory molecules in mice.
Immunology . 2015 Jun;145(2):268-78.  [PubMed]
5) Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T, Naka T.
Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.
Arthritis Rheumatol . 2015 May;67(8):2056-60.  [PubMed]
6) Natatsuka R, Takahashi T, Serada S, Fujimoto M, Ookawara T, Nishida T, Hara H, Nishigaki T, Harada E, Murakami T, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Kishimoto T, Mori M, Doki Y, Naka T.
Gene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis.
Br J Cancer . 2015 Jul 28;113(3):433-42.  [PubMed]
7) Tagami-Nagata N, Serada S, Fujimoto M, Tanemura A, Nakatsuka R, Ohkawara T, Murota H, Kishimoto T, Katayama I, Naka T.
Suppressor of cytokine signalling-1 induces significant preclinical antitumor effect in malignant melanoma cells.
Exp Dermatol . 2015 Nov;24(11):864-71.  [PubMed]
8) Iwahashi C, Fujimoto M, Nomura S, Serada S, Nakai K, Ohguro N, Nishida K, Naka T.
CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
Exp Eye Res . 2015 Nov;140:53-64.  [PubMed]
9) Hiramatsu K, Serada S, Kobiyama K, Nakagawa S, Morimoto A, Matsuzaki S, Ueda Y, Fujimoto M, Yoshino K, Ishii KJ, Enomoto T, Kimura T, Naka T.
CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
Cancer Sci . 2015 Oct;106(10):1474-8.  [PubMed]

2014

1) Sadaoka T, Serada S, Kato J, Hayashi M, Gomi Y, Naka T, Yamanishi K, Mori Y.
Varicella-zoster virus ORF49 functions in the efficient production of progeny virus through its interaction with essential tegument protein ORF44.
J Virol. 2014 Jan;88(1):188-201. [PubMed]
2) Ota M, Serada S, Naka T, Mori Y.
MHC class I molecules are incorporated into human herpesvirus-6 viral particles and released into the extracellular environment.
Microbiol Immunol. 2014 Feb;58(2):119-25.  [PubMed]
3) Matsuzaki S, Enomoto T, Serada S, Yoshino K, Nagamori S, Morimoto A, Yokoyama T, Kim A, Kimura T, Ueda Y, Fujita M, Fujimoto M, Kanai Y, Kimura T, Naka T.
Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.
Int J Cancer. 2014 Apr 15;134(8):1796-809.  [PubMed]
4) Oji Y, Tatsumi N, Fukuda M, Nakatsuka S, Aoyagi S, Hirata E, Nanchi I, Fujiki F, Nakajima H, Yamamoto Y, Shibata S, Nakamura M, Hasegawa K, Takagi S, Fukuda I, Hoshikawa T, Murakami Y, Mori M, Inoue M, Naka T, Tomonaga T, Shimizu Y, Nakagawa M, Hasegawa J, Nezu R, Inohara H, Izumoto S, Nonomura N, Yoshimine T, Okumura M, Morii E, Maeda H, Nishida S, Hosen N, Tsuboi A, Oka Y, Sugiyama H.
The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.
Int J Oncol. 2014 May;44(5):1461-9.  [PubMed]
5) Kotobuki Y, Yang L, Serada S, Tanemura A, Yang F, Nomura S, Kudo A, Izuhara K, Murota H, Fujimoto M, Katayama I, Naka T.
Periostin accelerates human malignant melanoma progression by modifying the melanoma microenvironment.
Pigment Cell Melanoma Res. 2014 Jul;27(4):630-9. [PubMed]
6) Yang L, Murota H, Serada S, Fujimoto M, Kudo A, Naka T, Katayama I.
Histamine contributes to tissue remodeling via periostin expression.
J Invest Dermatol. 2014 Aug;134(8):2105-2113. [PubMed]
7) Morimoto A, Serada S, Enomoto T, Kim A, Matsuzaki S, Takahashi T, Ueda Y, Yoshino K, Fujita M, Fujimoto M, Kimura T, Naka T.
Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner.
Oncotarget. 2014 Sep 15;5(17):7776-87.  [PubMed]

2013

1) Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T.
SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
Int J Cancer. 2013 Jan 15;132(2):459-71. [PubMed]
2) Yokoyama T, Enomoto T, Serada S, Morimoto A, Matsuzaki S, Ueda Y, Yoshino K, Fujita M, Kyo S, Iwahori K, Fujimoto M, Kimura T, Naka T.
Plasma membrane proteomics identifies BST2 as a potential therapeutic target in endometrial carcinoma.
Int J Cancer. 2013 Jan 15;132(2):472-84. [PubMed]
3) Shinzaki S, Kuroki E, Iijima H, Tatsunaka N, Ishii M, Fujii H, Kamada Y, Kobayashi T, Shibukawa N, Inoue T, Tsujii M, Takeishi S, Mizushima T, Ogata A, Naka T, Plevy SE, Takehara T, Miyoshi E.
Lectin-based immunoassay for aberrant IgG glycosylation as the biomarker for Crohn's disease.
Inflamm Bowel Dis. 2013 Feb;19(2):321-31. [PubMed]
4) Nishioka C, Ikezoe T, Furihata M, Yang J, Serada S, Naka T, Nobumoto A, Kataoka S, Tsuda M, Udaka K, Yokoyama A.
CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
Int J Cancer. 2013 May 1;132(9):2006-19. [PubMed]
5) He P, Kuhara H, Tachibana I, Jin Y, Takeda Y, Tetsumoto S, Minami T, Kohmo S, Hirata H, Takahashi R, Inoue K, Nagatomo I, Kida H, Kijima T, Naka T, Morii E, Kawase I, Kumanogoh A.
Calretinin mediates apoptosis in small cell lung cancer cells expressing tetraspanin CD9.
FEBS Open Bio. 2013 May 10;3:225-30. [PubMed]
6) Tang H, Serada S, Kawabata A, Ota M, Hayashi E, Naka T, Yamanishi K, Mori Y.
CD134 is a cellular receptor specific for human herpesvirus-6B entry.
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9096-9. [PubMed]
7) Yamada M, Mugnai G, Serada S, Yagi Y, Naka T, Sekiguchi K.
Substrate-attached materials are enriched with tetraspanins and are analogous to the structures associated with rear-end retraction in migrating cells.
Cell Adhesion & Migration . Cell Adh Migr. 2013 May-Jun;7(3):304-14. [PubMed]
8) Ishii H, Tanabe S, Ueno M, Kubo T, Kayama H, Serada S, Fujimoto M, Takeda K, Naka T, Yamashita T.
ifn-γ-dependent secretion of IL-10 from Th1 cells and microglia/macrophages contributes to functional recovery after spinal cord injury.
Cell Death Dis. 2013 Jul 4;4:e710. [PubMed]
9) Umegaki-Arao N, Tamai K, Nimura K, Serada S, Naka T, Nakano H, Katayama I.
Karyopherin alpha2 is essential for rRNA transcription and protein synthesis in proliferative keratinocytes.
PLoS One. 2013 Oct 3;8(10):e76416. [PubMed]
10) Shimada K, Serada S, Fujimoto M, Nomura S, Nakatsuka R, Harada E, Iwahori K, Tachibana I, Takahashi T, Kumanogoh A, Kishimoto T, Naka T.
Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells.
Cancer Sci. 2013 Nov;104(11):1483-91. [PubMed]
11) Takahashi T, Serada S, Ako M, Fujimoto M, Miyazaki Y, Nakatsuka R, Ikezoe T, Yokoyama A, Taguchi T, Shimada K, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Mori M, Doki Y, Naka T, Nishida T.
New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis.
Int J Cancer. 2013 Dec 1;133(11):2737-43. [PubMed]

2012

1) Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, Fujimoto M, Tanaka T, Naka T, Kishimoto T, Katayama I.
Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma.
Am J Pathol. 2012 Jan;180(1):165-76. [PubMed]
2) Souma Y, Nishida T, Serada S, Iwahori K, Takahashi T, Fujimoto M, Ripley B, Nakajima K, Miyazaki Y, Mori M, Doki Y, Sawa Y, Naka T.
Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells.
Int J Cancer . Int J Cancer. 2012 Sep 15;131(6):1287-96. [PubMed]
3) Kotobuki Y, Tanemura A, Yang L, Itoi S, Wataya-Kaneda M, Murota H, Fujimoto M, Serada S, Naka T, Katayama I.
Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris.
Pigment Cell Melanoma Res. 2012 Mar;25(2):219-30. [PubMed]
4) Serada S, Fujimoto M, Terabe F, Iijima H, Shinzaki S, Matsuzaki S, Ohkawara T, Nezu R, Nakajima S, Kobayashi T, Plevy SE, Takehara T, Naka T.
Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis.
Inflamm Bowel Dis. 2012 Nov;18(11):2169-79. [PubMed]
5) Ontsuka K, Kotobuki Y, Shiraishi H, Serada S, Ohta S, Tanemura A, Yang L, Fujimoto M, Arima K, Suzuki S, Murota H, Toda S, Kudo A, Conway SJ, Narisawa Y, Katayama I, Izuhara K, Naka T.
Periostin, a matricellular protein, accelerates cutaneous wound repair by activating dermal fibroblasts.
Exp Dermatol. 2012 May;21(5):331-6. [PubMed]
6) Iwahori K, Suzuki H, Kishi Y, Fujii Y, Uehara R, Okamoto N, Kobayashi M, Hirashima T, Kawase I, Naka T.
Serum HE4 as a diagnostic and prognostic marker for lung cancer.
Tumour Biol. 2012 Aug;33(4):1141-9. [PubMed]
7) Uebi T, Itoh Y, Hatano O, Kumagai A, Sanosaka M, Sasaki T, Sasagawa S, Doi J, Tatsumi K, Mitamura K, Morii E, Aozasa K, Kawamura T, Okumura M, Nakae J, Takikawa H, Fukusato T, Koura M, Nish M, Hamsten A, Silveira A, Bertorello AM, Kitagawa K, Nagaoka Y, Kawahara H, Tomonaga T, Naka T, Ikegawa S, Tsumaki N, Matsuda J, Takemori H.
Involvement of SIK3 in glucose and lipid homeostasis in mice.
PLoS One. 2012;7(5):e37803. [PubMed]
8) Tajiri K, Imanaka-Yoshida K, Matsubara A, Tsujimura Y, Hiroe M, Naka T, Shimojo N, Sakai S, Aonuma K, Yasutomi Y.
Suppressor of cytokine signaling 1 DNA administration inhibits inflammatory and pathogenic responses in autoimmune myocarditis.
J Immunol. 2012 Aug 15;189(4):2043-53. [PubMed]
9) Yang L, Serada S, Fujimoto M, Terao M, Kotobuki Y, Kitaba S, Matsui S, Kudo A, Naka T, Murota H, Katayama I.
Periostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma.
PLoS One.2012;7(7):e41994. [PubMed]
10) Ishii H, Jin X, Ueno M, Tanabe S, Kubo T, Serada S, Naka T, Yamashita T.
Adoptive transfer of Th1-conditioned lymphocytes promotes axonal remodeling and functional recovery after spinal cord injury.
Cell Death Dis. 2012 Aug 9;3:e363. [PubMed]

2011

1) * Terabe F, Fujimoto M, Serada S, Shinzaki S, Iijima H, Tsujii M, Hayashi N, Nomura S, Kawahata H, Jang MH, Miyasaka M, Mihara M, Ohsugi Y, Kishimoto T, Naka T.
Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis.
Inflamm Bowel Dis. 2011 Feb;17(2):491-502. [PubMed]
2) Iwahori K, Serada S, Fujimoto M, Nomura S, Osaki T, Lee CM, Mizuguchi H, Takahashi T, Ripley B, Okumura M, Kawase I, Kishimoto T, Naka T.
Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.
Int J Cancer. 2011 Aug 15;129(4):1005-17.  . [PubMed]
3) Fujimoto M, Nakano M, Terabe F, Kawahata H, Ohkawara T, Han Y, Ripley B, Serada S, Nishikawa T, Kimura A, Nomura S, Kishimoto T, Naka T.
The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells.
J Immunol. 2011 Jan 1;186(1):32-40. [PubMed]
4) Haruta H, Ohguro N, Fujimoto M, Hohki S, Terabe F, Serada S, Nomura S, Nishida K, Kishimoto T, Naka T.
Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3264-71.  [PubMed]
5) Yamashita T, Iwakura T, Matsui K, Kawaguchi H, Obana M, Hayama A, Maeda M, Izumi Y, Komuro I, Ohsugi Y, Fujimoto M, Naka T, Kishimoto T, Nakayama H, Fujio Y.
IL-6-mediated Th17 differentiation through RORγt is essential for the initiation of experimental autoimmune myocarditis.
Cardiovascular Research . Cardiovasc Res. 2011 Sep 1;91(4):640-8.  [PubMed]
6) Nomura T, Abe Y, Kamada H, Shibata H, Kayamuro H, Inoue M, Kawara T, Arita S, Furuya T, Yamashita T, Nagano K, Yoshikawa T, Yoshioka Y, Mukai Y, Nakagawa S, Taniai M, Ohta T, Serada S, Naka T, Tsunoda S, Tsutsumi Y.
Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.
J Control Release. 2011 Jan 5;149(1):8-14. [PubMed]

2010

1) * Serada S, Fujimoto M, Ogata A, Terabe F, Hirano T, Iijima H, Shinzaki S, Nishikawa T, Ohkawara T, Iwahori K, Ohguro N, Kishimoto T, Naka T.
iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases.
Ann Rheum Dis. 2010 Apr;69(4):770-4. [PubMed]
2) Akita H, Kogure K, Moriguchi R, Nakamura Y, Higashi T, Nakamura T, Serada S, Fujimoto M, Naka T, Futaki S, Harashima H.
Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation.
J Control Release. 2010 May 10;143(3):311-7. [PubMed]
3) * Ripley BJ, Fujimoto M, Serada S, Ohkawara T, Nishikawa T, Terabe F, Matsukawa Y, Stephanou A, Knight RA, Isenberg DA, Latchman DS, Kishimoto T, Naka T.
Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expression.
Int Immunol. 2010 May;22(5):359-66. [PubMed]
4) * Hohki S, Ohguro N, Haruta H, Nakai K, Terabe F, Serada S, Fujimoto M, Nomura S, Kawahata H, Kishimoto T, Naka T.
Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
Exp Eye Res. 2010 Aug;91(2):162-70. [PubMed]

2009

1) * Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, Ripley B, Miyatake T, Fujita M, Lee CM, Morimoto K, Fujimoto M, Kimura T, Naka T.
Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
Int J Cancer. 2009 Nov 15;125(10):2316-22. [PubMed]
2) Kimura A, Naka T, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T.
Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses.
J Exp Med. 2009 Aug 31;206(9):2027-35. [PubMed]
3) Tanaka S, Yoshimoto T, Naka T, Nakae S, Iwakura Y, Cua D, Kubo M.
Natural occurring IL-17 producing T cells regulate the initial phase of neutrophil mediated airway responses.
J Immunol. 2009 Dec 1;183(11):7523-30. [PubMed]

2008

1) * Takahashi T, Naka T, Fujimoto M, Serada S, Horino J, Terabe F, Hirota S, Miyoshi E, Hirai T, Nakajima K, Nishitani A, Souma Y, Sawa Y, Nishida T.
Aberrant expression of glycosylation in juvenile gastrointestinal stromal tumors.
Proteomics Clin Appl. 2008 Sep;2(9):1246-54. [PubMed]
2) Nakashima T, Yokoyama A, Onari Y, Shoda H, Haruta Y, Hattori N, Naka T, Kohno N.
Suppressor of cytokine signaling 1 inhibits pulmonary inflammation and fibrosis.
J Allergy Clin Immunol. 2008 May;121(5):1269-76. [PubMed]
3) Seki E, Kondo Y, Iimuro Y, Naka T, Son G, Kishimoto T, Fujimoto J, Tsutsui H, Nakanishi K.
Demonstration of cooperative contribution of MET- and EGFR-mediated STAT3 phosphorylation to liver regeneration by exogenous suppressor of cytokine signalings.
J Hepatol. 2008 Feb;48(2):237-45. [PubMed]
4) Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, Tanaka T, Kawase I, Naka T, Yoshizaki K.
Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression.
J Immunol. 2008 Mar 1;180(5):3492-501. [PubMed]
5) Yamaguchi H, Takagi J, Miyamae T, Yokota S, Fujimoto T, Nakamura S, Ohshima S, Naka T, Nagata S.
Milk fat globule EGF factor 8 in the serum of human patients of systemic lupus erythematosus.
J Leukoc Biol. 2008 May;83(5):1300-7. [PubMed]
6) Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S, Yoshida H, Nishikawa T, Terabe F, Ohkawara T, Takahashi T, Ripley B, Kimura A, Kishimoto T, Naka T.
IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis.
Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9041-6. [PubMed]
7) * Horino J, Fujimoto M, Terabe F, Serada S, Takahashi T, Soma Y, Tanaka K, Chinen T, Yoshimura A, Nomura S, Kawase I, Hayashi N, Kishimoto T, Naka T.
Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice.
Int Immunol. 2008 Jun;20(6):753-62. [PubMed]
8) Yu CR, Mahdi RM, Liu X, Zhang A, Naka T, Kishimoto T, Egwuagu CE.
SOCS1 regulates CCR7 expression and migration of CD4+ T cells into peripheral tissues.
J Immunol. 2008 Jul 15;181(2):1190-8. [PubMed]
9) Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T.
Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells.
Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9721-6. [PubMed]
10) * Iwahori K1, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T.
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
Lung Cancer. 2008 Oct;62(1):45-54. [PubMed]
11) * Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, Ohsugi Y, Nishikawa T, Ripley B, Kimura A, Kishimoto T, Naka T.
Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Arthritis Rheum. 2008 Dec;58(12):3710-9. [PubMed]

2007

1) Shoda H, Yokoyama A, Nishino R, Nakashima T, Ishikawa N, Haruta Y, Hattori N, Naka T, Kohno N.
Overproduction of collagen and diminished SOCS1 expression are causally linked in fibroblasts from idiopathic pulmonary fibrosis.
Biochem Biophys Res Commun. 2007 Feb 23;353(4):1004-10. [PubMed]
2) Kanatani Y, Usui I, Ishizuka K, Bukhari A, Fujisaka S, Urakaze M, Haruta T, Kishimoto T, Naka T, Kobayashi M.
Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression.
Diabetes. 2007 Mar;56(3):795-803. [PubMed]
3) Ohshima M, Yokoyama A, Ohnishi H, Hamada H, Kohno N, Higaki J, Naka T.
Overexpression of suppressor of cytokine signalling-5 augments eosinophilic airway inflammation in mice.
Clin Exp Allergy. 2007 May;37(5):735-42. [PubMed]
4) * He P, Naka T, Serada S, Fujimoto M, Tanaka T, Hashimoto S, Shima Y, Yamadori T, Suzuki H, Hirashima T, Matsui K, Shiono H, Okumura M, Nishida T, Tachibana I, Norioka N, Norioka S, Kawase I.
Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer.
Cancer Sci. 2007 Aug;98(8):1234-40. [PubMed]
5) Kimura A, Naka T, Kishimoto T.
IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells.
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12099-104. [PubMed]
6) * Serada S, Fujimoto M, Takahashi T, He P, Hayashi A, Tanaka T, Hagihara K, Yamadori T, Mochizuki M, Norioka N, Norioka S, Kawase I, Naka T.
Proteomic analysis of autoantigens associated with systemic lupus erythematosus.
Proteomics-clinical applications. Proteomics Clin Appl. 2007 Feb;1(2):185-91. [PubMed]

2006

1) Hirano T, Higa S, Arimitsu J, Naka T, Ogata A, Shima Y, Fujimoto M, Yamadori T, Ohkawara T, Kuwabara Y, Kawai M, Matsuda H, Yoshikawa M, Maezaki N, Tanaka T, Kawase I, Tanaka T.
Luteolin, a flavonoid, inhibits AP-1 activation by basophils.
Biochem Biophys Res Commun. 2006 Feb 3;340(1):1-7. [PubMed]
2) * Ouyang X, Fujimoto M, Nakagawa R, Serada S, Tanaka T, Nomura S, Kawase I, Kishimoto T, Naka T.
SOCS-2 interferes with myotube formation and potentiates osteoblast differentiation through upregulation of JunB in C2C12 cells.
J Cell Physiol. 2006 May;207(2):428-36. [PubMed]
3) Arimitsu J, Hirano T, Higa S, Kawai M, Naka T, Ogata A, Shima Y, Fujimoto M, Yamadori T, Hagiwara K, Ohgawara T, Kuwabara Y, Kawase I, Tanaka T.
IL-18 gene polymorphisms affect IL-18 production capability by monocytes.
Biochem Biophys Res Commun. 2006 Apr 21;342(4):1413-6. [PubMed]
4) Hirano T, Arimitsu J, Higa S, Naka T, Ogata A, Shima Y, Fujimoto M, Yamadori T, Ohkawara T, Kuwabara Y, Kawai M, Kawase I, Tanaka T.
Luteolin, a flavonoid, inhibits CD40 ligand expression by activated human basophils.
Int Arch Allergy Immunol. 2006;140(2):150-6. Epub 2006 Apr 4. [PubMed]
5) * Abe T, Nomura S, Nakagawa R, Fujimoto M, Kawase I, Naka T.
Osteoblast differentiation is impaired in SOCS-1-deficient mice.
J Bone Miner Metab. 2006;24(4):283-90. [PubMed]
6) Ogata Y, Osaki T, Naka T, Iwahori K, Furukawa M, Nagatomo I, Kijima T, Kumagai T, Yoshida M, Tachibana I, Kawase I.
Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation.
Neoplasia. 2006 Oct;8(10):817-25. [PubMed]

2005

1) Imanaka K, Tamura S, Fukui K, Ito N, Kiso S, Imai Y, Naka T, Kishimoto T, Kawata S, Shinomura Y; Kansai Viral Hepatitis Research Group.
Enhanced expression of suppressor of cytokine signalling-1 in the liver of chronic hepatitis C: possible involvement in resistance to interferon therapy.
J Viral Hepat. 2005 Mar;12(2):130-8. [PubMed]
2) Seki E, Tsutsui H, Iimuro Y, Naka T, Son G, Akira S, Kishimoto T, Nakanishi K, Fujimoto J.
Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration.
Hepatology. 2005 Mar;41(3):443-50. [PubMed]
3) Inaba M, Saito H, Fujimoto M, Sumitani S, Ohkawara T, Tanaka T, Kouhara H, Kasayama S, Kawase I, Kishimoto T, Naka T.
Suppressor of cytokine signaling 1 suppresses muscle differentiation through modulation of IGF-I receptor signal transduction.
Biochem Biophys Res Commun. 2005 Mar 25; [PubMed]
4) Kimura A, Naka T, Muta T, Takeuchi O, Akira S, Kawase I, Kishimoto T.
Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT.
Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17089-94. Epub 2005 Nov 15. [PubMed]

2004

1) * Fujimoto M, Tsutsui H, Xinshou O, Tokumoto M, Watanabe D, Shima Y, Yoshimoto T, Hirakata H, Kawase I, Nakanishi K, Kishimoto T, Naka T.
Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases.
Int Immunol. 2004 Feb;16(2):303-14. [PubMed]
2) Komazaki T, Nagai H, Emi M, Terada Y, Yabe A, Jin E, Kawanami O, Konishi N, Moriyama Y, Naka T, Kishimoto T.
Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers.
Jpn J Clin Oncol. 2004 Apr;34(4):191-4. [PubMed]
3) Hirano T, Higa S, Arimitsu J, Naka T, Shima Y, Ohshima S, Fujimoto M, Yamadori T, Kawase I, Tanaka T.
Flavonoids such as luteolin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by activated human basophils.
Int Arch Allergy Immunol. 2004 Jun;134(2):135-40. [PubMed]
4) Kimura A, Naka T, Kawase I, and Kishimoto T.
SOCS-1 suppresses TNF-α-induced apoptosis through the regulation of Jak activation.
Int Immunol . 2004; 16: 991-999, [PubMed]
5) Watanabe D, Ezoe S, Fujimoto M, Kimura A, Saito Y, Nagai H, Tachibana I, Matsumura I, Tanaka T, Kanegane H, Miyawaki T, Emi M, Kanakura Y, Kawase I, Naka T, Kishimoto T.
Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines.
Br J Haematol. 2004 Sep;126(5):726-35. [PubMed]

2003

1) Nagai H, Naka T, Terada Y, Komazaki T, Yabe A, Jin E, Kawanami O, Kishimoto T, Konishi N, Nakamura M, Kobayashi Y, Emi M.
Hypermethylation assiciated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas.
J Hum Genet. 2003;48(2):65-9. [PubMed]
2) Ohnishi H, Yokoyama A, Yasuhara Y, Watanabe A, Naka T, Hamada H, Abe M, Nishimura K, Higaki J, Ikezoe J, Kohno N.
Circulating KL-6 levels in patients with drug induced pneumonitis.
Thorax . 2003 Oct;58(10):872-5. [PubMed]

2002

1) Sakuda S, Tamura S, Yamada A, Miyagawa Ji, Yamamoto K, Kiso S, Ito N, Imanaka K, Wada A, Naka T, Kishimoto T, Kawata S, Matsuzawa Y.
Activation of signal transducer and activator transcription 3 and expression of suppressor of cytokine signal 1 during liver regeneration in rats.
J Hepatol. 2002 Mar;36(3):378-84. [PubMed]
2) Fujiwara H, Morita A, Kobayashi H, Hamano K, Fujiwara Y, Hirai K, Yano M, Naka T, Saeki Y.
Infiltrating eosinophils and eotaxin: their association with idiopathic eosinophilic esophagitis.
Ann Allergy Asthma Immunol. 2002 Oct;89(4):429-32. [PubMed]
3) * Fujimoto M, Tsutsui H, Yumikura-Futatsugi S, Ueda H, Xingshou O, Abe T, Kawase I, Nakanishi K, Kishimoto T, Naka T.
A regulatory role for suppressor of cytokine signaling-1 in T(h) polarization in vivo.
Int Immunol. 2002 Nov;14(11):1343-50. [PubMed]
4) Seki Y, Hayashi K, Matsumoto A, Seki N, Tsukada J, Ransom J, Naka T, Kishimoto T, Yoshimura A, Kubo M.
Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation.
Proc. Natl. Acad. Sci. USA . 2002 Oct 1;99(20):13003-8. [PubMed]
5) Nakagawa R, Naka T, Tsutsui H, Fujimoto M, Kimura A, Abe T, Seki E, Sato S, Takeuchi O, Takeda K, Akira S, Yamanishi K, Kawase I, Nakanishi K, Kishimoto T.
SOCS-1 participates in negative regulation of LPS responses.
Immunity. 2002 Nov;17(5):677-87. [PubMed]

2001

1) Kawazoe Y, Naka T, Fujimoto M, Kohzaki H, Morita Y, Narazaki M, Okumura K, Saitoh H, Nakagawa R, Uchiyama Y, Akira S, Kishimoto T.
Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation.
J Exp Med. 2001 Jan 15;193(2):263-9. [PubMed]
2) * Naka T, Tsutsui H, Fujimoto M, Kawazoe Y, Kohzaki H, Morita Y, Nakagawa R, Narazaki M, Adachi K, Yoshimoto T, Nakanishi K, Kishimoto T.
SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-and IL-4 signaling in vivo.
Immunnity . 2001; 14: 535-545. [PubMed]

2000年以前

1) Morita Y, Naka T, Kawazoe Y, Fujimoto M, Narazaki M, Nakagawa R, Fukuyama H, Nagata S, Kishimoto T.
Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts.
Proc. Natl. Acad. Sci. USA . 2000 May 9;97(10):5405-10. [PubMed]
2) Saito H, Morita Y, Fujimoto M, Narazaki M, Naka T, Kishimoto T.
IFN regulatory factor-1-mediated transcriptional activation of mouse STAT-induced STAT inhibitor-1 gene promoter by IFN-gamma.
J Immunol. 2000 Jun 1;164(11):5833-43. [PubMed]
3) Fujimoto M, Naka T, Nakagawa R, Kawazoe Y, Morita Y, Tateishi A, Okumura K, Narazaki M, Kishimoto T.
Defective thymocyte development and perturbed homeostasis of T cells in STAT-induced STAT inhibitor-1/suppressors of cytokine signaling-1 transgenic mice.
J Immunol. 2000 Aug 15;165(4):1799-806. [PubMed]
4) * Naka T, Matsumoto T, Narazaki M, Fujimoto M, Morita Y, Ohsawa Y, Saito H, Nagasawa T, Uchiyama Y, Kishimoto T.
Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice.
Proc Natl Acad Sci USA . 1998 Dec 22;95(26):15577-82. [PubMed]
5) Narazaki M, Fujimoto M, Matsumoto T, Morita Y, Saito H, Kajita T, Yoshizaki K, Naka T, Kishimoto T.
Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling.
Proc. Natl. Acad. Sci. USA . 1998 Oct 27;95(22):13130-4. [PubMed]
6) Minamoto S, Ikegame K, Ueno K, Narazaki M, Naka T, Yamamoto H, Matsumoto T, Saito H, Hosoe S, Kishimoto T.
Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3.
Biochem Biophys Res Commun. 1997 Aug 8;237(1):79-83. [PubMed]
7) * Naka T, Narasaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T.
Structure and function of a new STAT-induced STAT inhibitor.
Nature. 1997 Jun 26;387(6636):924-9. [PubMed]
8) Ochi H, Tanaka T, Katada Y, Naka T, Aitani M, Hashimoto S, Maeda K, Toyoshima K, Igarashi T, Suemura M, Kishimoto T.
Peripheral blood T lymphocytes and basophils, freshly isolated from house-dust-mite-sensitive patients, produce interleukin-4 in response to allergen-specific stimulation.
Int Arch Allergy Immunol. 1996 Nov;111(3):253-61. [PubMed]
9) Ochi H, Tanaka T, Katada Y, Naka T, Aitani M, Hashimoto S, Maeda K, Toyoshima K, Igarashi T, Suemura M.
Functional disturbance of naive T lymphocytes in very high IgE producers: depletion of Interleukin-4-induced Interleukin-4-producing cells.
Int Art Allergy Immunol. 1996 Mar;109(3):236-42. [PubMed]
10) Fujiwara M, Kikutani H, Suematu S, Naka T, Yoshida K, Yoshida N, Tanaka T, Suemura M, Matsumoto N, Kojima S, Kishimoto T, Yoshida N.
The absence of IgE antibody-mediated augmentation of immune responses in CD23-deficient mice.
Proc. Natl. Acad. Sci. USA. 1994 Jul 19;91(15):6835-9. [PubMed]
11) Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H.
The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation.
Immunity. 1994 Jun;1(3):167-78. [PubMed]